Create an Account
  1. Home
  2. Specialty
  3. Cataract & Refractive

DED Origin Story: Understanding the Role of MGD

DED Origin Story Understanding the Role of MGD
Media formats available:
Details
Presenters

  • Overview

    This on-demand webinar features Program Chair Alice T. Epitropoulos, MD, FACS, along with Michael Greenwood, MD, and John D. Sheppard, MD, MMSc, discussing how meibomian gland dysfunction interacts with dry eye disease and the latest data on new and emerging treatments. This content was captured during a live symposium. This program was recorded prior to the approval of perfluorohexyloctane ophthalmic solution (formerly known as NOV03). 

    This activity is supported by an unrestricted educational grant from Bausch + Lomb.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Diagnose dry eye disease (DED) by subtype based on signs and symptoms
    • Articulate how meibomian gland dysfunction (MGD) interacts with DED
    • Summarize the latest data on treatments for MGD
    • Compare the pipeline agents nearest to regulatory approval and explain their mechanisms of action

    • Accreditation

       Provided by Evolve Medical Education 

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Alice T. Epitropoulos, MD, FACS

      Alice T. Epitropoulos, MD, FACS

      Private practice

      Ophthalmic Surgeons & Consultants of Ohio

      and the Eye Center of Columbus, Ohio

      Clinical Associate Professor

      The Ohio State University

      Wexner Medical Center

      Columbus, OH


      Michael Greenwood, MD

      Michael Greenwood, MD

      Cataract, Refractive, Cornea, and Glaucoma Surgeon
      Vance Thompson Vision
      Fargo, ND


      John D. Sheppard, MD, MMSc, FACS

      John D. Sheppard, MD, MMSc, FACS

      Founding Partner, Virginia Eye Consultants
      Professor of Ophthalmology, Microbiology, Molecular Biology
      Ophthalmology Residency Research Director
      Eastern Virginia Medical School
      Division Medical Director, EyeCare Partners
      Medical Director
      Lions Medical Eye Bank of Eastern Virginia
      Norfolk, VA


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Alice T. Epitropoulos, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisor: Oyster Point Pharma. Consultant: Aldeyra, Allergan/AbbVie, Bausch + Lomb, BioTissue, Bruder, Dompé, EyePoint Pharmaceuticals, Imprimis, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Physician Recommended Nutriceuticals, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, and Visus. Grant/Research Support: AimMax Therapeutics, Bausch + Lomb, and Sylentis. Primary Investigator: Third phase 3 FDA clinical trial for Dextenza. Property Right/Patent Holder: Hilco. Speaker’s Bureau: Allergan/AbbVie, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, and Sun Pharma.

      Michael Greenwood, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, BVI, Carl Zeiss Meditec, Equinox, Imprimis, Ivantis, New World Medical, Nevakar, and Ocular Therapeutix. Grant/Research Support: Alcon, Glaukos, Ocular Therapeutix, Sight Sciences, and STAAR Surgical. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon, Allergan, Carl Zeiss Meditec, Equinox, Glaukos, Imprimis, Johnson & Johnson Vision, New World Medical, Ocular Therapeutix, Sight Sciences, STAAR Surgical, and Valeant. Stock/Shareholder: Equinox.

      John D. Sheppard, MD, MMSc, FACS,has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Aldeyra Therapeutics, Allergan, Allysta Pharmaceuticals, Avedro, Bausch + Lomb, BioTissue, Bruder Healthcare, Clementia Pharmaceuticals, Dompé, EyeGate, EyePoint Pharmaceuticals, Glaukos, Hovione, Johnson & Johnson Vision, Kala Pharmaceuticals, Lacri Sciences, LayerBio, Mallinckrodt, Novaliq, Novartis, Noveome Biotherapeutics, Ocular Therapeutix, Omeros, Oyster Point Pharma, Quidel, ScienceBased Health, Shire, Sun Pharma, Takeda Pharmaceuticals USA, TearLab, Tear Solutions, and TopiVert. Grant/Research Support: Alcon, Bausch + Lomb, Chengdu Kanghong Biotechnology, Clearside Biomedical, EyeGate, Hovione, Kala Pharmaceuticals, Mallinckrodt, and Visus Pharmaceuticals. Speaker’s Bureau: Alcon, Bausch + Lomb, BioTissue, Dompé, and Mallinckrodt. Shareholder: Claris Bio, Doctors Optimal Formula, Eyedetec Medical, EyeRxResearch, Eyevance, Lacrisciences, LayerBio, Noveome Biotherapeutics, Oyster Point Pharma, ProVision Network, Rapid Pathogen Screening, Scientifically Developed Solutions, Strathspey Crowne, and TearLab.

      The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free